Patents by Inventor FENGQING LI

FENGQING LI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11712434
    Abstract: The present invention provides a compound of the formula I, a process for its preparation and the use of a medicament for the treatment of cancer. The compound of the present invention has an inhibitory effect on various cancer cells and can be biologically converted into the active drug Linifanib in vitro (in plasma) to inhibit the proliferation of tumor cells, especially liver cancer cells, at a lower dose.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: August 1, 2023
    Assignee: 3D MEDICINES (BEIJING) CO., LTD.
    Inventors: John Gong, Yihui Lin, Fengqing Li, Fangqiang Tang
  • Patent number: 11351151
    Abstract: The present invention provides a compound exemplified by Formula I: a process for its preparation and the use of a medicament for the treatment of cancer. The compound of the present invention has an inhibitory effect on various cancer cells and can be biologically converted into the active drug Linifanib in vitro (in liver homogenate and spleen homogenate) to inhibit the proliferation of tumor cells, especially liver cancer cells, at a lower dose.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: June 7, 2022
    Assignee: 3D MEDICINES (BEIJING) CO., LTD.
    Inventors: John Gong, Yihui Lin, Fengqing Li, Fangqiang Tang
  • Publication number: 20200038371
    Abstract: The present invention provides a compound of the formula I, a process for its preparation and the use of a medicament for the treatment of cancer. The compound of the present invention has an inhibitory effect on various cancer cells and can be biologically converted into the active drug Linifanib in vitro (in liver homogenate and spleen homogenate) to inhibit the proliferation of tumor cells, especially liver cancer cells, at a lower dose.
    Type: Application
    Filed: November 17, 2017
    Publication date: February 6, 2020
    Applicant: 3D Medicines (Beijing) Co., Ltd.
    Inventors: JOHN GONG, YIHUI LIN, FENGQING LI, FANGQIANG TANG
  • Publication number: 20190365711
    Abstract: The present invention provides a compound of the formula I, a process for its preparation and the use of a medicament for the treatment of cancer. The compound of the present invention has an inhibitory effect on various cancer cells and can be biologically converted into the active drug Linifanib in vitro (in plasma) to inhibit the proliferation of tumor cells, especially liver cancer cells, at a lower dose.
    Type: Application
    Filed: November 17, 2017
    Publication date: December 5, 2019
    Applicant: 3D MEDICINES (BEIJING) CO., LTD.
    Inventors: JOHN GONG, YIHUI LIN, FENGQING LI, FANGQIANG TANG